HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

Table 4 Clinical and histological features of sixty patients subjected to neoadjuvant chemotherapy with docetaxel plus epirubicin. Patients were divided according to clinical response as objective response (OR) and no response (NR) groups.

	OR (n)	NR (n)	P	Test
Age
Median (range)	51,5 (35 – 67)	47,5 (29 – 68)	0.3	Student t
≤ 45 anos	12	7
>45 anos	35	7	0.1	Fisher
Menopausal Status
Post	24	8
Pre	22	6	0.9	x²
CT cycle (range)	3 (2 – 5)	3 (2 – 4)	0.4	Mann-Whitney
CS
IIA	8	4
IIB	15	4
IIIA	5	2
IIIB	14	4
IIIC	3	0	0.78	x²
Grade
I	10	6
II	27	5
III	8	3	0.2	x²
ER
Positive	32	12
Negative	12	2	0.48	Fisher
PR
Positive	20	7
Negative	25	7	0.76	Fisher
ER/PR
Positive	16	7
Negative	22	7	0.75	Fisher
P53
Positive	16	2
Negative	30	12	0.19	Fisher
P21
Positive	15	5
Negative	31	9	1	Fisher
HER-2
Positive	10	1
Negative	36	13	0.43	Fisher

OR = objective response; NR = no response; n = number of patients; CT = chemotherapy; CS = clinical staging; Grade = histological grade (Bloom-Richardson); ER = estrogen receptor; PR = progesterone receptor.

ISSN: 1471-2407